CD5 and leukemia: To characterize the underlying mechanism involved in the cooperative effect between lenalidomide and rituximab, we analyzed the effect of lenalidomide on CD20 expression on leukemia cells (CD5+/CD19+) after 2, 7, and 14 days of treatment.